45
Participants
Start Date
October 11, 2018
Primary Completion Date
August 31, 2025
Study Completion Date
August 31, 2026
decitabine
Decitabine is thought to act as an anti-metabolite. It seems to work by having a toxic effect on the abnormal bone marrow cells.
DC/AML fusion cells
An investigational agent that tries to help the immune system to recognize and fight against cancer cells
RECRUITING
Beth Israel Deaconess Medical Center, Boston
RECRUITING
Dana Farber Cancer Institute, Boston
National Cancer Institute (NCI)
NIH
Dana-Farber Cancer Institute
OTHER
Beth Israel Deaconess Medical Center
OTHER